Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 7/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12619928 | 0.93 | NR1I2 (0.44) | NR1I2PRKCAMMP12KCNH2CYP3A4 | |
| SCHEMBL15949104 | 0.92 | NR1I2 (0.39) | NR1I2PRKCAMMP12KCNH2CYP3A4 | |
| SCHEMBL12070890 | 0.92 | NR1I2 (0.41) | NR1I2PRKCAMMP12KCNH2CYP3A4 | |
| SCHEMBL12071862 | 0.91 | NR1I2 (0.43) | NR1I2PRKCAMMP12KCNH2CYP3A4 | |
| SCHEMBL12619890 | 0.89 | NR1I2 (0.41) | NR1I2PRKCAMMP12KCNH2CYP3A4 | |
| SCHEMBL12620094 | 0.88 | NR1I2 (0.43) | NR1I2PRKCAMMP12KCNH2CYP3A4 | |
| SCHEMBL13940357 | 0.85 | NR1I2 (0.44) | NR1I2PRKCAMMP12KCNH2CYP3A4 | |
| SCHEMBL12619930 | 0.85 | NR1I2 (0.42) | NR1I2PRKCAMMP12KCNH2CYP3A4 | |
| SCHEMBL12653510 | 0.85 | NR1I2 (0.46) | NR1I2PRKCAMMP12KCNH2CYP3A4 | |
| SCHEMBL19316369 | 0.85 | NR1I2 (0.44) | NR1I2PRKCAMMP12KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9127010-B2 | Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-08 | — | — | US | claimed |
| EP-2585438-B1 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID | JANSSEN R & D IRELAND (IE) | 2014-08-20 | — | — | EP | claimed |
| EP-2585438-A1 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID | Janssen R&D Ireland (IE) | 2013-05-01 | — | — | EP | claimed |
| US-20130102777-A1 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2--ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID | JANSSEN R&D IRELAND (IL) | 2013-04-25 | — | — | US | claimed |
| WO-2011161232-A1 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID | TIBOTEC PHARMACEUTICALS (IE) | 2011-12-29 | — | — | WO | claimed |
| EP-2310396-B1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-06 | — | — | EP | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-20150329482-A1 | Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid | JANSSEN SCIENCES IRELAND UC (IE) | 2015-11-19 | — | — | US | disclosed |
| US-20150329482-A1 | Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid | JANSSEN SCIENCES IRELAND UC (IE) | 2015-11-19 | — | — | US | disclosed |
| US-20150329482-A1 | Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid | JANSSEN SCIENCES IRELAND UC (IE) | 2015-11-19 | — | — | US | disclosed |
| US-20150329482-A1 | Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid | JANSSEN SCIENCES IRELAND UC (IE) | 2015-11-19 | — | — | US | disclosed |
| US-20130102777-A1 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2--ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID | JANSSEN R&D IRELAND (IL) | 2013-04-25 | — | — | US | disclosed |
| US-20130102777-A1 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2--ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID | JANSSEN R&D IRELAND (IL) | 2013-04-25 | — | — | US | disclosed |
| WO-2011161232-A1 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID | TIBOTEC PHARMACEUTICALS (IE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161232-A1 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID | TIBOTEC PHARMACEUTICALS (IE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161232-A1 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID | TIBOTEC PHARMACEUTICALS (IE) | 2011-12-29 | — | — | WO | disclosed |
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-05-05 | — | — | US | disclosed |
| WO-2010003658-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | IDO1, HCCS, CCNI | NR1I2 234/4885PRKCA 3619/4885MMP12 3816/4885 |
| US-20130102777-A1 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2--ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID | HTR3C, CHAT, KDM5C | NR1I2 2234/4885PRKCA 3711/4885MMP12 1834/4885 |
| US-20150329482-A1 | Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid | HTR2A, HTR3C, HTR6 | NR1I2 2347/4885PRKCA 4017/4885MMP12 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.